Posted by Michael Wonder on 07 May 2021
Updated agenda for the July 2021 PBAC meeting
7 May 2021 - The agenda for the July 2021 PBAC meeting has been updated.
A summary of changes to the agenda is provided at the end of the agenda document.
The updated agenda includes 16 additions/revisions:
- Five early re-entry resubmissions received
- Seven scheduled for review under the process for reviewing positive recommendations not accepted by the applicant
- Four minor revisions (not discussed further)
Early re-entry resubmissions - rejections from the March 2021 meeting
- Darolutamide
- Cedazuridine with decitabine
- Melatonin
- Riprentinib
- Venetoclax
Review of PBAC recommendations
- Budesonide - March 2019
- Enoxaparin sodium - July 2020
- Ramucirumab - March 2018
- Secukinumab - March 2016
- Sevelamer carbonate - November 2017
- Tenofovir alafenamide fumarate - March 2017
- Triglycerides - medium chain (Nutrini Peptisorb) - March 2019
We will discuss the issue of unresolved PBAC recommendations in a future issue of MAESTrO Daily.
Read PBAC meeting agenda
Posted by:
Michael Wonder